REGN — Regeneron Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $66.35bn
- $60.31bn
- $14.34bn
Regeneron says it expects to avoid new US pharma tariffs
Brief: Eylea HD Approved By FDA As First And Only Injectable Anti-Vegf With Dosing Intervals Up To 5 Months
U.S. RESEARCH ROUNDUP- Howmet Aerospace, Nike, Oracle
Regeneron rises after announcing positive trial data on weight-loss drug
Brief: Olatorepatide Obesity Treatment Licensed by Regeneron Demonstrates Positive Phase 3 Results in Chinese Patients
Brief: EMA's CHMP Recommended Granting A Marketing Authorisation For Mcombriax
Brief: Sanofi And Regeneron’S Dupixent Approved In The U.S. For Allergic Fungal Rhinosinusitis
Brief: Garetosmab Biologics License Application Accepted For FDA Priority Review
Ocular Therapeutix's eye drug superior to Regeneron's Eylea in late-stage trial (updated)
Ocular Therapeutix's eye drug superior to Regeneron's Eylea in late-stage trial
Regeneron bets added cholesterol benefit will help its obesity drug stand out
Regeneron rises after quarterly profit beat
Regeneron beats quarterly profit estimates on Dupixent strength
Regeneron Pharma Q4 adjusted EPS beats estimates on demand for Dupixent, EYLEA
Sanofi targets high single digit sales growth in 2026, plans share buyback (updated)
Eli Lilly signs up to $1.12 billion deal with private gene-editing firm Seamless
Intellia jumps as FDA lifts hold on gene‑editing trial for rare nerve disease
Focus: Some drugmakers quietly concerned about legal risk with speedy FDA review program
Focus: Some drugmakers quietly concerned about legal risk with speedy FDA review program